NCT03965013View on ClinicalTrials.gov

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

December 14, 2019

Study Completion Date

December 14, 2019

Conditions
Diabetes Mellitus, Type 1Healthy Volunteers
Interventions
DRUG

NNC0268-0965

2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2

DRUG

Placebo

A single dose of placebo given in Part 1

DRUG

insulin glargine

Insulin glargine given at a fixed dose level of 0.5 U/kg

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY